Table 2.
Characteristics of Asian HIV-infected adolescents (n=250)
| Total | Male | Female | |
|---|---|---|---|
| N | 250 | 121 | 129 |
| Age at ART initiation | 7 (4–10) | 7 (3–10) | 7 (4–10) |
| HIV exposure N (%) | |||
| Perinatal | 234 (93) | 116 (96) | 118 (91) |
| Blood products/sexual abuse | 2 (1) | 0 (0) | 2 (2) |
| Unknown | 14 (6) | 5 (4) | 9 (7) |
| Median (IQR) duration on ART, years | 7.1 (4.7–10.2) | 7.1 (4.9–10.8) | 7.0 (4.7–10.2) |
| Median (IQR) current CD4 cell count, cells/mm3 | 676 (484–884), n=240 | 676 (520–886), n=117 | 677 (470–882), n=123 |
| Median (IQR) current CD4 percentage | 27 (22–32), n=231 | 26 (22–30), n=113 | 29 (22–33), n=118 |
| ART regimens (%) | |||
| NNRTI-based | 154 (62) | 73 (60) | 81 (63) |
| PI-based | 81 (32) | 41 (34) | 40 (31) |
| Others | 15 (6) | 7 (6) | 8 (6) |
| HIV-RNA <400 copies/mL, N (%) | 160 (83), n=194 | 79 (86) | 81 (79) |
| HIV-RNA >1000 copies/mL, N (%) | 28 (14), n=194 | 10 (11) | 18 (18) |
IQR: interquartile range; ART: antiretroviral therapy; NNRTI: non-nucleoside reverse transcriptase inhibitor; PI: protease inhibitor